Tyra Biosciences to Participate in Upcoming Investor Conferences

Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company based in Carlsbad, California, is set to participate in several upcoming investor conferences scheduled for late February and March 2026. The company focuses on developing next-generation precision medicines targeting Fibroblast Growth Factor Receptor (FGFR) biology, a crucial area in oncology and genetically defined conditions.

Tyra is slated to present at the 36th Annual Oppenheimer Life Sciences Healthcare Conference on February 26, 2026, kicking off the series of events. This will be followed by participation in the 46th Annual TD Cowen Healthcare Conference in Boston on March 4, where they will conduct both hybrid presentations and one-on-one investor meetings. Additionally, Tyra will engage in one-on-one meetings at the Leerink Global Healthcare Conference from March 8-11, and at both the 2026 Jefferies Biotech on the Beach Summit and the Barclays 28th Annual Global Healthcare Conference taking place in Miami from March 9-12.

These conferences provide an excellent platform for Tyra to highlight its innovative pipeline and the company's proprietary precision medicine platform, SNÅP. This technology enables rapid drug design, predicting genetic mutations that may lead to resistance against existing therapies. Key products in Tyra's pipeline include oral dabogratinib, a promising FGFR3 inhibitor aimed at treating various forms of cancer, including urothelial carcinoma and non-muscle invasive bladder cancer. Other developments include TYRA-430 and TYRA-200, targeting FGFR4-driven cancers and intrahepatic cholangiocarcinoma, respectively.

A live webcast of the presentations will be accessible on Tyra’s Investor Relations page, allowing stakeholders to stay informed about the company’s progress and scientific advancements.

Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology firm, has strategically positioned itself by participating in several upcoming investor conferences. This presents a timely opportunity for potential investors to evaluate the company's progress and pipeline in the expanding precision medicine sector, particularly in Fibroblast Growth Factor Receptor (FGFR) biology.

Participation in the 36th Annual Oppenheimer Life Sciences Healthcare Conference and the 46th Annual TD Cowen Healthcare Conference indicates Tyra's commitment to engaging with potential investors and stakeholders. These appearances will feature a blend of virtual formats and one-on-one meetings, enabling direct interaction to discuss their innovative pipeline and the stronger market position they aim to create with their lead product, oral dabogratinib.

Tyra's unique SNÅP platform, which accelerates precision drug design, serves as a strong differentiator in the competitive biotech landscape. By focusing on FGFR-driven cancers, the company targets a significant niche within oncology therapeutics, which could attract interest from both institutional and retail investors. Given the recent biotech investment climate, which shows renewed interest in precision therapies, Tyra could benefit from heightened visibility and strategic discussions at these conferences.

Additionally, the development of pipeline candidates like TYRA-430 and TYRA-200 relies on their innovative methodologies to tackle difficult-to-treat cancers. Given the growing focus on targeted therapies, Tyra's advancements could potentially lead to strong market positioning and revenue generation.

As investors gear up for these conferences, careful consideration should be given to Tyra’s performance metrics, updates on clinical studies, and regulatory progress. With a rich pipeline and ongoing engagement initiatives, Tyra Biosciences represents a compelling watch for investors seeking exposure to the rapidly evolving biotechnology sector.